<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: During B-cell development, precursor B cells transiently express the pre-B-cell receptor composed of μ heavy chain complexed with VpreB and λ5 surrogate light chain <z:chebi fb="1" ids="15841">polypeptides</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Recent profiling studies unexpectedly revealed abundant transcripts of one member of the VpreB family, VpreB3, in a subset of mature B cells and Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>DESIGN AND METHODS: Here we used a novel antibody to investigate the <z:mpath ids='MPATH_458'>normal</z:mpath> expression pattern of VpreB3 protein in human hematopoietic and lymphoid tissues, and to determine whether VpreB3 could serve as a useful diagnostic biomarker for select B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: We found that VpreB3 protein is normally expressed by precursor B cells in bone marrow and by a subset of <z:mpath ids='MPATH_458'>normal</z:mpath> germinal center B cells in secondary lymphoid organs </plain></SENT>
<SENT sid="4" pm="."><plain>Among lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, we found an association between VpreB3 expression and B-cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with c-MYC abnormalities </plain></SENT>
<SENT sid="5" pm="."><plain>VpreB3 was highly expressed in <z:hpo ids='HP_0000001'>all</z:hpo> cases of Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, whether of endemic or <z:hpo ids='HP_0003745'>sporadic</z:hpo> origin (44/44 cases, 100%), <z:hpo ids='HP_0000001'>all</z:hpo> cases of B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, unclassifiable, with features intermediate between diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (5/5 cases, 100%), and the majority of diffuse large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> harboring a c-MYC translocation (15/18 cases, 83%) </plain></SENT>
<SENT sid="6" pm="."><plain>The expression of VpreB3 in diffuse large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> without a c-MYC translocation was associated with c-MYC polysomy in 25/75 cases (33%) but only rarely observed in diffuse large B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> lacking a c-MYC abnormality (9/98 cases, 9%) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: We conclude that for B-cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with features suggesting a possible c-MYC translocation, such as intermediate to large cell size and high proliferation rate, the presence of VpreB3 should prompt subsequent confirmatory genetic testing, whereas the absence of VpreB3 is virtually always associated with <z:mp ids='MP_0002169'>wild-type</z:mp> c-MYC alleles </plain></SENT>
</text></document>